Three different long-term paths, not two
When people think about the long-term future of GLP-1 treatment, the framing is often binary: stay on your current dose indefinitely, or stop entirely. There's a meaningful third option worth understanding — tapering to a lower, still-active maintenance dose rather than either extreme. Our discussion guide on talking to your doctor about stopping or tapering treatment covers how to raise this conversation; this guide covers how the dosing side of that decision actually works.
What the research suggests about dose reduction vs. stopping
According to PubMed, a 2026 clinical trial (SURMOUNT-MAINTAIN) directly compared continuing tirzepatide at its full effective dose, reducing to a lower dose, or switching to placebo after an initial weight-loss period. Both continuing at the full dose and reducing to a lower dose maintained significantly more weight loss than switching to placebo, though the full dose maintained somewhat more than the reduced dose (see our guide on the history of GLP-1 medications for more on this trial). This is meaningful evidence that a reduced maintenance dose is a genuine middle path — better than stopping, if a full dose isn't necessary or desired long-term.
Why someone might choose to taper rather than stay at full dose or stop
- Reaching a goal weight or body composition and wanting to shift from active weight loss to long-term maintenance, where a lower dose may be sufficient to hold results.
- Side effect burden that's worth trading some effect for improved day-to-day comfort, without giving up the medication's benefit entirely.
- Cost considerations, if a lower dose has different pricing or coverage dynamics — worth exploring alongside your prescriber and insurance rather than defaulting to full discontinuation for cost reasons alone.
- A deliberate transition toward diet- and exercise-driven maintenance, using a lower dose as a supportive bridge rather than the primary driver of continued results.
How this decision typically gets made
This is a gradual, monitored process rather than an abrupt change — your prescriber will typically want to track how you respond to a lower dose (weight trend, appetite, any symptom changes) before confirming it as your new stable point, similar in spirit to how titration up works, just in reverse.
The bottom line
Long-term GLP-1 treatment isn't just "stay at full dose forever" or "stop completely" — tapering to a lower, still-effective maintenance dose is a legitimate, evidence-supported middle path worth discussing with your prescriber if your goals, side effect tolerance, or life circumstances change over the course of treatment.